But Wait, There’s More!

Jun 20, 2024

On a crossword puzzle, we came across this 5-letter clue: “But wait! There’s more!”

The answer if you grew up in the ‘80s like we did was immediately evident: Ginsu. Click on the video above to watch the so-bad-it’s-good infomercial for the Ginsu knife that introduced the now-iconic phrase, “But wait, there’s more.” (We read that Ginsu is a made-up word although co-creator of the infomercial, Barry Becher, reportedly joked it meant “I never have to work again”). LOL.

Lead EpicentRx small molecule, RRx-001 (nibrozetone), also a made-up name, and shorthand for “wow, this is a lot of work” (but, of course, only in the best possible way) 😂, chemosensitizes tumors and chemoprotects normal tissues as suggested by preclinical and clinical data. This is the basis for the ongoing randomized, controlled Phase 3 clinical trial with RRx-001 plus a platinum doublet in third-line or beyond small cell lung cancer (SCLC) called REPLATINUM.

But wait! There’s more!

It also is a radiosensitizer and a radioprotector, as suggested by preclinical and clinical data. This data is the basis for FDA Fast Track designation and for a randomized, controlled Phase 2b clinical trial called KEVLARx with cisplatin, intensity-modulated radiation therapy (IMRT).

But wait! There’s more!

RRx-001 (nibrozetone) will also start a clinical trial in endometriosis this year with Dr. Andrew Horne from the University of Edinburgh in Scotland.

But wait! There’s more!

Dr. Richard Gordon from Queensland Australia continues to study RRx-001 as a stand-alone, disease-modifying treatment for Parkinson’s disease and for Amyotrophic Lateral Sclerosis (ALS)/Motor Neuron Disease (MND, having been awarded important grants by the Michael J. Fox Foundation, Shake It Up Australia, and Fight MND.

But wait! There’s SO, SO MUCH more!

RRx-001 (nibrozetone) has demonstrated activity against Alzheimer’s, sickle cell anemia, nonalcoholic steatohepatitis (NASH), SARS-CoV-2/COVID-19, Gram-negative sepsis, pulmonary fibrosis, diabetic nephropathy, multiple sclerosis, inflammatory bowel disease, chemotherapy-induced diarrhea, asthma, monosodium urate crystals (MSU)-induced peritonitis, and malaria.

Seriously, we could go on and on, really, we could, but let’s end with, “There’s NO more!”

The NO in this case stands for nitric oxide, which RRx-001 releases only under hypoxic conditions. This release of nitric oxide, a vasodilator, is responsible for exercise enhancement, and for protection against stroke, myocardial infarction, pulmonary hypertension, vasculopathies, and hemorrhagic shock.

RRx-001 (nibrozetone) can be found in several prominent clinical trial centers across the United States and soon in England, Ginsu knives not included.